Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2011-05-03
2011-05-03
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S185100, C424S193100, C424S195110, C424S198100, C424S277100, C514S002600, C530S326000, C530S402000, C530S403000
Reexamination Certificate
active
07935350
ABSTRACT:
Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2
eu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2
eu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK (SEQ ID NO: 2) residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.
REFERENCES:
patent: 5726023 (1998-03-01), Cheever et al.
patent: 2003/0235594 (2003-12-01), Humphreys et al.
Sotiriadou, N. N., et al. Cancer Immunology Immunotherapy, in press (online Sep. 8, 2006).
Bertolino, P. and Rabourdin-Combe, C., Crit Rev Immunol 16:359-379 (1996).
Bodmer, H., et al., Science 263:1284-1286 (1994).
Xu, M., et al., Mol Immunol 31:723-731 (1994).
Daibata, M., et al., Mol Immunol 31:255-260 (1994).
Reyes, V. E., et al., Ann N Y Acad Sci 730:338-341 (1994).
Bakke, O. and Dobberstein B., Cell 63:707-716 (1990).
Lamb, C. A. and Cresswell, P., J Immunol 148:3478-3482 (1992).
Blum, J. S. and Cresswell, P., Proc Natl Acad Sci U S A 85:3975-3979 (1988).
Nguyen, Q. Vet al., Hum Immunol 24:153-163 (1989).
Shi, G. P., et al., J Exp Med 191:1177-1186 (2000).
Riese, R. J., et al., Immunity 4:357-366 (1996).
Hiltbold, E. M. and Roche, P. A., Curr Opin Immunol 14:30-35 (2002).
Riberdy, J. M., et al., Nature 360:474-477 (1992).
Gautam, A. M., et al., Proc Natl Acad Sci U S A 92:335-339 (1995).
Romagnoli, P. and Germain, R. N., J Exp Med 180:1107-1113 (1994).
Morris, P., et al., Nature 368:551-554 (1994).
Denzin, L. K. and Cresswell, P., Cell 82:155-165 (1995).
Xu, M., et al., Arzneimittelforschung 49:791-799 (1999).
Adams, S., et al., Arzneimittelforschung 47:1069-1077 (1997).
Lu, S., et al., J Immunol 145:899-904 (1990).
Adams, S., and Humphreys, R. E., Eur J Immunol 25:1693-1702 (1995).
Humphreys, R. E., et al., Vaccine 18:2693-2697 (2000).
Ghosh P, et al., Nature 378:457-462 (1995).
Stevanovic, S. and Rammensee, H. G., Behring Inst Mitt: 7-13 (1994).
Rammensee, H. G., et al., Immunogenetics 41:178-228 (1995).
Hakenberg, J., et al., Appl Bioinformatics 2:155-158 (2003).
Knutson, K. L., et al., Clin Cancer Res 8:1014-1018 (2002).
Phan, G. Q., et al., J Immunother 26:349-356 (2003).
Brinkman, J. A., et al., Expert Opin Biol Ther 4:181-198 (2004).
Hersey, P., et al., Cancer Immunol Immunother 54:208-218 (2005).
Xu, M., et al., Scand J Immunol 54:39-44 (2001).
Gillogly, M. E., et al., Cancer Immunol Immunother 53:490-496 (2004).
Kallinteris, N. L., et al., Vaccine 21:4128-4132 (2003).
Kallinteris, N. L., et al., Vaccine 23:2336-2338 (2005).
Kallinteris, N. L., et al., J Immunother 28:352-358 (2005).
Touloukian, C. E., et al., J Immunol 164:3535-3542 (2000).
Kallinteris, N. L., et al., Frontiers in Bioscience: 46-58 (2006).
Fleckenstein, B., et al., Semin Immunol 11:405-416 (1999).
Joshi, R. V., et al., Biochemistry 39:3751-3762 (2000).
Wang, R. F., Immunol Rev 188:65-80 (2002).
Sette A., and Fikes, J., Curr Opin Immunol 15:461-470 (2003).
Hanson, H. L. et al., J Immunol 172:4215-4224 (2004).
Wong, R., et al., Clin Cancer Res 10:5004-5013 (2004).
Hung, K., et al., J Exp Med 188:2357-2368 (1998).
Surman, D. R., et al., J Immunol 164:562-565 (2000).
Welsh, R. M., et al., Annu Rev Immunol 22:711-743 (2004).
Knutson, K. L. and Disis, M. L., Cancer Immunol Immunother (2005).
Rocha B. and Tanchot, C., Curr Opin Immunol 16:259-263 (2004).
Janssen, E. M., et al., Nature 434:88-93 (2005).
Dissanayake, S. K., et al., Cancer Res 64:1867-1874 (2004).
Ossendorp, F., et al., J Exp Med 187:693-702 (1998).
Dudley, M. E., et al., Science 298:850-854 (2002).
Robbins, P. F., et al., J Immunol 169:6036-6047 (2002).
Gao, F. G., et al., Cancer Res 62:6438-6441 (2002).
Yu, P., et al., J Exp Med 197:985-995 (2003).
Anthony, P. A., et al., J Immunol 174:2591-2601 (2005).
Mandic, M., et al., J Immunol 174:1751-1759 (2005).
Lu, J., et al., J Immunol 172:4575-4582 (2004).
Slager, E. H., et al., J Immunol 172:5095-5102 (2004).
Delcayre, A. and Le Pecq, J. B., Opin Mol Ther. 8:31-8 (2006).
Sanders, M. T., et al., Immunol Cell Biol. 83:119-28 (2005).
Nagata, Y., et al., Proc Natl Acad Sci U S A 99:10629-34 (2002).
Tobian, A. et al., J Immunol 172:5277-86 (2004).
Zimmerman, D. H. and Rosenthal, K. S., Front Biosci 10:790-798 (2005).
Frahke, E. D., et al., Vaccine 17:1201-5 (1999).
Nagata, T et al., Vaccine 20:105-14 (2001).
Humphreys Robert E.
Xu Minzhen
Antigen Express, Inc.
Farrell Kevin M.
Harris Alana M.
Holleran Anne L
Pierce Atwood LLP
LandOfFree
Ii-key/Her-2/neu hybrid cancer vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ii-key/Her-2/neu hybrid cancer vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ii-key/Her-2/neu hybrid cancer vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684538